Skip to main content

Table 1 Overall outcome analysis in pemetrexed maintenance study based on histology subgroups

From: Updates in non-small cell lung cancer - insights from the 2009 45th annual meeting of the American Society of Clinical Oncology

 

Pemetrexed n = 441)

Placebo (n = 222)

HR (95% CI)

P Value

Overall Median PFS, months

4.0

2.0

0.60 (0.49-0.73)

< 0.0001

Median PFS in Nonsquamous cases (n = 481)

4.4

1.8

0.47 (0.37-0.60)

< 0.00001

Median PFS in Squamous cases (n = 182)

2.4

2.5

1.03 (0.77-1.50)

Not Significant

Overall Median OS, months

13.4

10.6

0.79 (0.65-0.95)

0.012

Overall Median in Nonsquamous cases (n = 481)

15.5

10.3

0.70 (0.56-0.88)

0.002

Overall Median in Squamous cases (n = 182)

9.9

10.8

1.07 (0.49-0.73)

Not Significant

  1. PFS, progression free survival; OS, overall survival; HR, hazard ratio; Reference: [9]